Tempus to acquire cancer test maker Personalis for $1.5B
Tempus AI agreed to acquire cancer test maker Personalis for $1.5 billion.
Tempus AI
Tempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Its platform collects and analyzes clinical and molecular data to enable physicians and researchers to make data-driven decisions in oncology, cardiology, and other disease areas.
Company Info
Sector:AI in healthcare / precision medicine
Headquarters:Chicago, Illinois, United States
Founded:2015
Website:www.tempus.com
Upcoming Milestones & Key Dates
Q3 2026
M&A
Personalis acquisition close ($1.5B)
Q2 2026 (reported)
Earnings
Q2 earnings + NGS volume update
Late 2026
Product
AI model pipeline expansion announcements
Clinical Development Pipeline
Tempus xT (solid tumor NGS panel)
Target: NGS-based tumor profilingTempus xR (RNA-seq)
Target: RNA expression analysisPersonalis NeXT Personal® (post-acquisition)
Target: Tumor-informed ctDNA assayRecent News
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis.
Leadership Team
Eric P. Lefkofsky
Founder & Chief Executive Officer
James J. Rogers
Chief Financial Officer
Ryan Fukushima
Chief Operating Officer
Careers & Job Openings